UroGen Pharma Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, UroGen Pharma stock has a consensus rating of "Strong Buy" and an average price target of $36.44. The average 1-year stock price forecast is 27.50% higher than the current stock price, while the lowest is $18 (-37.02%) and the highest is $45 (+57.45%).

Price Target: $36.44 (+27.50%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$18	$36.44	$40	$45
Change	-37.02%	+27.50%	+39.96%	+57.45%

Analyst Ratings

The average analyst rating for UroGen Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	4	4	4	3	3	3
Buy	3	3	3	3	3	3
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	7	7	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $45	Strong Buy	Reiterates	$45	+57.45%	May 18, 2026
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $40 → $45	Strong Buy	Maintains	$40 → $45	+57.45%	May 11, 2026
Leland Gershell Oppenheimer	Oppenheimer	Buy Maintains $34 → $40	Buy	Maintains	$34 → $40	+39.96%	May 7, 2026
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $33	Strong Buy	Maintains	$33	+15.47%	Mar 31, 2026
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $33	Strong Buy	Maintains	$33	+15.47%	Mar 2, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

268.54M

from 109.79M

144.60%

from 109.79M

Revenue Next Year

445.49M

from 268.54M

65.89%

from 268.54M

EPS This Year

-0.85

from -3.19

EPS Next Year

1.47

from -0.85

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	48.04M	64.36M	82.71M	90.40M	109.79M	268.54M	445.49M
Revenue Growth	307.17%	33.96%	28.52%	9.29%	21.45%	144.60%	65.89%
EPS	-4.96	-4.81	-3.55	-2.96	-3.19	-0.85	1.47
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	19.50
No. Analysts	-	-	-	-	-	11	11

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	318.7M	601.2M
Avg	268.5M	445.5M
Low	236.3M	355.7M

Revenue Growth

Revenue Growth	2026	2027
High	190.3%	123.9%
Avg	144.6%	65.9%
Low	115.2%	32.5%

EPS Forecast

EPS	2026	2027
High	-0.27	3.26
Avg	-0.85	1.47
Low	-1.67	0.25

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.